Summary

• ASP Isotopes (ASPI) is rated Sell due to premature growth narrative, high capital intensity, and heavy execution risk versus current $6.89 share price.
• My DCF valuation implies a $2.40 fair value, reflecting the need for ASPI to prove commercial scale, margin conversion, and financing capacity.
• Recent business updates show segment progress—radiopharma leads revenue, Si-28 and Yb-176 shipments targeted for 2026, and Renergen Phase 1 drilling completed early.
• Despite $290.5M liquidity, ASPI faces negative cash flow, widening losses, and a 25% probability of failure, making current risk-reward unattractive.

Investment Thesis

I rate ASP Isotopes (ASPI) a Sell. The company surely has an attractive strategic narrative and exposure to currently scarce isotopes with interesting medical applications, together with potential businesses in semiconductor materials, HALEU nuclear

89 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.